Different causes of 18-Fluorine-labelled-2-deoxy-2-fluoro-D-glucose uptake in a patient with non-Hodgkin lymphoma

Gazzetta Medica Italiana Archivio per le Scienze Mediche

Volumn 171, Issue 3, 2012, Pages 351-356

  Niccoli Asabella, A ^a   Notaristefano, A ^a   Pisani, A R ^a   Iuele, F ^a   Altini, C ^a   Rubini, G ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Arthritis, infectious; Fluorodeoxyglucose F18; Lymphoma non Hodgkin

Indexed keywords

BLEOMYCIN; CEFAZOLIN; CIPROFLOXACIN; COTRIMOXAZOLE; CYTARABINE; FLUORODEOXYGLUCOSE F 18; GENTAMICIN; GLUCOSE; METHOTREXATE; SULESOMAB TC 99M; VINCRISTINE;

ADVERSE OUTCOME; AGED; ANTIBIOTIC THERAPY; ARTICLE; ASTHENIA; BACTERIAL ARTHRITIS; BLOOD CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; ESCHERICHIA COLI INFECTION; FEMALE; FEVER; GLUCOSE TRANSPORT; HIP PAIN; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LEUKOCYTE; NORMOCHROMIC NORMOCYTIC ANEMIA; NUCLEAR MAGNETIC RESONANCE IMAGING; RADIATION DOSE; SIDE EFFECT;

EID: 84867291375     PISSN: 03933660     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Jhanwar YS, Straus DJ. The role of PET in lymphoma. J Nud Med 2006;47:1326-34.
2. Lowe VJ, Wiseman GA. Assessment of lymphoma therapy using (18)F-FDG PET. J Nucl Med 2002;43:1028-30.
3. Geipel U. Pathogenic organisms in hip joint infections. Int J Med Sci 2009;6:234-40.
4. Jerusalem G, Beguin Y, Fassotte MF et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001;86:266-73.
5. Castellucci P, Nanni C, Farsad M et al. Potential pitfalls of 18F-FDG PET in a large series of patients treated for malignant lymphoma: prevalence and scan interpretation. Nucl Med Commun 2005;26:689-94.
6. Jerusalem G, Beguin Y, Fassotte MF et al. Wholebody positron emission tomography using 18Ffluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999;94:429-33.
7. Iasi Cr, Lu P, Blaufox MD. A metanalysis of 18F-2-deoxy-2fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:1066-74.
8. Stumpe KM, Urbinelli M, Steinert HC, Glanzmann C, Buck A, von Schulthess GK. Whole body positron emission tomography using flurodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med 1998;25:721-8.
9. Cook GJ, Fogelman I, Maisey MN. Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: potential for error in interpretation. Semin Nucl Med 1996;26:308-14.
10. Engel H, Steinert H, Buck A et al. Whole-body PET: physiological and artifactual fluorodeoxyglucose accumulations. J Nucl Med 1996;37:441-6.
11. Shreve PD, Anzai Y, Wahl RL. Pitfalls in oncologic diagnosis with FDG PET imaging: physiologic and benign variants. Radiographics 1999;19:61-77.
12. Bhargava P, Zhuang H, Kumar R et al. Iatrogenic artifacts on whole-body 18F-FDG PET imaging. Clin Nucl Med 2004;29:429-39.
13. Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG-PET and PETAC oncologic imaging. Semin Nucl Med 2004;34:122-33.
14. Zhuang H. Alavi A. 18-fluorodeoxyglucose positron emission tomographic imaging in the detection and monitoring of infection and inflammation. Semin Nucl Med 2002;32:47-59.
15. Yan X, Jinhua Z, Xiang C et al. Elevated FDG Uptake in Right Middle Segmental Bronchus Impacted With Foreign Body. Clin Nucl Med 2009;34:241-2.
16. Bard H. Periarticular pathology of the hip. Rev Prat 2002;52:627-31.
17. Resnick D, Niwayama G. Entheses and enthesopathy: anatomical, pathological, and radiological correlation. Radiology 1983;146:1-9.
18. Yasuda S, Ide M, Takagi S et al. Elevated 18F-FDG uptake in skeletal muscle. Clin Nucl Med. 1998;23:111-2.
19. Bar-Shalom R. Muscle uptake of 18-fluorine fluorode-oxyglucose. Semin Nucl Med 2000;30:306-9.
20. Broski SM, Bou-Assaly WB, Gross MD, Lorraine M. Diffuse skeletal Muscle 18F-Fluorodeoxyglucose Uptake in advanced Primary Muscle non-Hodgkin's Lymphoma. Clin Nucl Med. 2009;34:251-3.
21. 18F-Fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease. Haematologica 2001;86:266-73.